Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2010

View Archived Issues

Cytomics claims novel antiproliferative agents for multidrug resistance cancer

GPR119 agonists for the treatment of obesity identified by iNovacia

Organon presents AMPA receptor agonists for neurodegenerative diseases

Bayer Schering Pharma discovers novel c-Met inhibitors for cancer therapy

Sunesis completes enrollment of phase Ib/II voreloxin trial

ACT Biotech confirms FDA acceptance of ACTB-1003 IND

Locked nucleic acid-based oligonucleotide suppresses HCV viremia in primates

Droxidopa restores contextual memory in mouse model of Down's syndrome

Cetuximab as first-line therapy for Menetrier's disease / News in Context

GlaxoSmithKline receives approval for Arepanrix H1N1 vaccine

Gentamicin induces readthrough of termination codons in Stuve-Wiedermann syndrome

Novartis obtains approval for new H1N1 flu vaccine

AFFiRiS discloses novel therapeutics for beta-amyloidoses

Novel monoamine reuptake inhibitors in development at SK Holdings

Inspire reports results of phase III Prolacria trial for dry eye

Somaxon provides update on Silenor NDA for the treatment of insomnia

Agennix expands phase III talactoferrin registration trial globally

Arzerra receives positive opinion for conditional approval in Europe for CLL

CytRx reports 2010 clinical and development milestones

GAA gene variants responsive to Pompe's disease candidate AT-2220 identified

OVATURE trial analysis to proceed following database lock

Sinovac presents recent developments for its vaccines

EMEA validates NicOx's MAA for naproxcinod in primary osteoarthritis

Pharming presents update on European CHMP's review of MAA for Rhucin in HAE

EMEA completes validation phase of MAA for Pfizer and Auxilium's Xiaflex

FDA grants marketing approval to Acorda's Ampyra to improve walking in MS patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.